Sharekhan

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

What’s Your Call?

Collective community sentiment on Beryl Drugs Ltd

Your Vote -

Buy

50.00%

Hold

0.00%

Sell

50.00%

50.00%

2 users have voted

No Records Found

Option Chain

Analyzes market sentiment, predicts Beryl Drugs Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Beryl Drugs Ltd. - NOTICE OF EVOTING FACILITY FOR 32ND ANNUAL GENERAL MEETING 2025

    2 Sep 2025, 4:50PM NOTICE OF EVOTING FACILITY FOR 32ND ANNUAL GENERAL MEETINF OF THE COMPANY
  • Beryl Drugs Ltd. - FIXES RECORD DATE FOR THE PURPOSE OF ANNUAL GENERAL MEETING OF THE COMPANY 23RD SEPTEMBER, 2025

    2 Sep 2025, 4:44PM NOTICE OF CUT OFF DATE(RECORD DATE) FOR THE PURPOSE OF ANNUAL GENERAL MEETING OF THE COMPANY 2025
  • Beryl Drugs Ltd. - FIXES BOOK CLOSURE FOR THE PURPOSE OF ANNUAL GENERAL MEETING OF THE COMPANY FROM 24TH SEPTEMBER, 2025 TO 3

    2 Sep 2025, 4:39PM NOTICE OF ANNUAL BOOK CLOSURE FOR THE PURPOSE OF ANNUAL GENERAL MEETING
  • Beryl Drugs Ltd. - 32ND ANNUAL GENERAL MEETING OF THE COMPANY WILL BE HELD ON 30TH SEPTEMBER, 2025 AT 11:00 AM AT Kanchan Pal

    2 Sep 2025, 4:35PM NOTICE OF 32ND ANNUAL GENERAL MEETING
  • Beryl Drugs Ltd. - Board Meeting Outcome for OUTCOME OF BOARD MEETING

    2 Sep 2025, 4:23PM OUTCOME OF BOARD MEETING
  • Beryl Drugs Ltd. - Board Meeting Intimation for Consideration And Approval Of The Board Report And Other Matters Related To 3

    25 Aug 2025, 7:55PM Beryl Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/09/2025 ,inter alia, to consider and appr
  • Beryl Drugs Q1 net profit down 94.59% at Rs 0.02 cr

    7 Aug 2025, 5:30PM The company reported standalone net profit of Rs 0.02 crore for the quarter ended June 30, 2025 as compared to Rs 0.37 crore in the same period last y
  • Beryl Drugs Ltd. - UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2025

    7 Aug 2025, 4:15PM UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2025
  • Beryl Drugs Ltd. - Board Meeting Outcome for OUTCOME OF BOARD MEETING

    7 Aug 2025, 4:06PM OUTCOME OF BOARD MEETING
  • Beryl Drugs Ltd. - Board Meeting Intimation for Consider And Approve The Unaudited Financial Results For The Quarter Ended 30

    29 Jul 2025, 5:10PM Beryl Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2025 ,inter alia, to consider and appr
  • Beryl Drugs Ltd. has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2025

    10 Jul 2025, 4:50PM As of June 2025, 26.38% is owned by Indian Promoters and 73.62% by Public. <p align=justify> Top four Promoters holding highest number of shares of Be
  • Beryl Drugs Ltd. - Compliance-57 (5) : intimation after the end of quarter

    5 Jul 2025, 3:09PM NON APPLICABILITY CERTIFICATE UNDER REGULATION 57(5) FOR THE QUARTER ENDED 30.06.2025
  • Beryl Drugs Ltd. - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    5 Jul 2025, 2:03PM Compliance Certificate under Regulation 74(5) for the quarter ended 30th June, 2025

Key fundamentals

Evaluate the intrinsic value of Beryl Drugs Ltd stock 

Name March-25 March-24 March-23 March-22 March-21
Assets 13.5773 14.0172 12.6085 12.5872 12.2693
Liabilities 13.5773 14.0172 12.6085 12.5872 12.2693
Equity 5.0937 5.0937 5.0937 5.0937 5.0936
Gross Profit 1.2324 2.2788 1.9451 0.408 1.4482
Net Profit 0.5789 0.7686 0.766 -0.659 0.2396
Cash From Operating Activities 2.6367 0.8203 2.4804 -0.2867 0.3777
NPM(%) 2.73 2.87 2.84 -4.51 1.7
Revenue 21.1462 26.7296 26.8878 14.6037 14.0929
Expenses 19.9138 24.4508 24.9427 14.1957 12.6446
ROE(%) 6.1 8.1 8.07 -6.95 2.52

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day

Peers

Other companies within the same industry or sector that are comparable to Beryl Drugs Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 807.60 -0.87 72.96 14.30 301.39 0.62
Lotus Eye Hospital and Institute Ltd 134.65 4.70 433.81 52.12 3.55 0.00
Bharat Immunological and Biologicals Corporation Ltd 22.17 2.45 0.00 108.21 -39.50 0.00
Astec Lifesciences Ltd 854.25 -2.56 0.00 49.15 -604.77 0.00

Company Info

1994 -The company was incorporated as a medicine pharmaceutical manufacturer. 2007 -The board of directors of the company at its meeting held on Nov.16, 2007 decided to issue 1.50 million equity shares and 2 million warrants to promoters and other strategic investors on preferential basis. -Board of the company had increased the authorized share capital of the company from Rs 5.50 crores to Rs 10.00 crores. 2008 -Board of directors of the company had approved to issue 35 lacs warrants to promoters and other strategic investors on preferential basis. 2015 -Beryl Drugs, MPPHSCL sign deal worth Rs 11.8 crores.

1994 -The company was incorporated as a medicine pharmaceutical manufacturer. 2007 -The board of directors of the company at its meeting held on Nov.16, 2007 decided to issue 1.50 million equity shares and 2 million warrants to promoters and other strategic investors on preferential basis. -Board of the company had increased the authorized share capital of the company from Rs 5.50 crores to Rs 10.00 crores. 2008 -Board of directors of the company had approved to issue 35 lacs warrants to promoters and other strategic investors on preferential basis. 2015 -Beryl Drugs, MPPHSCL sign deal worth Rs 11.8 crores.

Read More

Parent Organisation

Beryl Drugs Ltd.

Founded

24/08/1993

Managing Director

Mr.Sanjay Sethi

NSE Symbol

FAQ

The current price of Beryl Drugs Ltd is

The 52-week high for Beryl Drugs Ltd is

The market capitalization of Beryl Drugs Ltd is currently This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Beryl Drugs Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Beryl Drugs Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Beryl Drugs Ltd shares.

The CEO of Beryl Drugs Ltd is Mr.Sanjay Sethi, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT